February 25-27, 2020 | Vienna, Austria
www.ras-europe.com

RAS - Targeted Drug Discovery Europe
Finally Drug the “Undruggable” RAS

Advance Novel Target Site Discovery, Improve Drug-Like Properties & Accelerate the Translation of Robust Therapeutic Strategies to Finally Target RAS Mutants Successfully

Expert Speakers Include:

Julian Downward
Associate Research Director
Francis Crick Institute

Darryl McConnell
Senior Vice President & Research Site Head
Austria Boehringer Ingelheim

Laurent Debussche
Vice President, Global Head Molecular Oncology Research Therapeutic Area
Sanofi R&D

Steve Kelsey
President, Research & Development
Revolution Medicines

Grahame Mckenzie
Chief Scientific Officer
PhoreMost

Juan J. Perez
Chief Scientific Officer
Allinky Biopharma

Dwight V. Nissley
Director, Cancer Research Technology Program; NCI RAS Initiative
Frederick National Laboratory for Cancer Research

Stig Hansen
Chief Executive Officer
Carmot Therapeutics

Sreesha P. Srinivasa
Senior Vice President
Oblique Therapeutics

Tel: +44 203 141 8700  Email: info@hansonwade.com
The Only European Industry-Dedicated Meeting Focused On Drugging The “Undruggable” RAS

Advance Novel Target Site Discovery, Improve Drug-Like Properties & Accelerate the Translation of Robust Therapeutic Strategies to Finally Target RAS Mutants Successfully

After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins. The RAS-Targeted Drug Discovery Summit Europe is the only industry and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate.

Uniting the leading minds from large pharma, biotech and academia, this summit will help you advance novel target site discovery, improve drug-like properties and accelerate the translation of potent and mutation-specific RAS targeted therapeutic strategies into human clinical trials.

With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the RAS-Targeted Drug Discovery Summit Europe to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic.

Why Attend the RAS-Targeted Drug Discovery Summit Europe?

Benchmark against the latest strategies to finally drug the “undruggable” RAS family of proteins with insights from Boehringer Ingelheim, Sanofi & Bayer

Leverage the latest in vitro and in vivo data to optimise your anti-RAS drug discovery approach with insights from Francis Crick Institute, NCI RAS Initiative & Spanish National Cancer Research Center

Enable your RAS drug discovery efforts by harnessing the latest tools and technologies with insights from Carmot Therapeutics, Phormost & Allinky Biopharma

Overcome selectivity, potency and drug-like properties with insights from Oblique Therapeutics, Elicio Therapeutics & Revolution Medicines

Gain strategic and data-driven awareness of the translational and clinical outcomes of targeting RAS family of proteins with insights from Onconova Therapeutics, Targovax & The Christie NHS Foundation Trust

What are our speakers looking forward to?

I find it an exciting opportunity to share the recent developments in RAS research and synergise the efforts to target this important oncogene for the betterment of millions of patients.

Krishnaraj Rajalingam, Heisenberg Professor of Cell Biology, Cell Biology Unit, University Medical Center Mainz

This event will bring together key opinion leaders from both academia and drug discovery in order to deliver a truly translational meeting focused on how best to tackle oncogenic RAS.

Graeme Mckenzie, Chief Scientific Officer, PhoreMost
YOUR EXPERT SPEAKERS

Julian Downward
Associate Research Director
Francis Crick Institute

Mariano Barbacid
AXA.CNIO Professor of Molecular Oncology
CNIO (Spanish National Cancer Research Center)

Darryl McConnell
Senior Vice President & Research Site Head Austria
Boehringer Ingelheim

Dwight V. Nissley
Director, Cancer Research Technology Program; NCI RAS Initiative
Frederick National Laboratory for Cancer Research

Laurent Debussche
Vice President, Global Head Molecular Oncology Research Therapeutic Area
Sanofi R&D

Steve Kelsey
President, Research & Development
Revolution Medicines

Stig Hansen
Chief Executive Officer
Carmot Therapeutics

Graeme Mckenzie
Chief Scientific Officer
PhoreMost

Juan J. Perez
Chief Scientific Officer
Allinky Biopharma

Peter DeMuth
Vice President of Research
Elicio Therapeutics

Sreesha P. Srinivasa
Senior Vice President
Oblique Therapeutics

Bert Klebl
Managing Director & Chief Scientific Officer
Lead Discovery Center

Krishnaraj Rajalingam
Heisenberg Professor of Cell Biology, Cell Biology Unit
University Medical Center Mainz

Steven M. Fruchtman
President & Chief Executive Officer
Onconova Therapeutics

Erik D. Wiklund
Chief Business Officer
Targovax

Colin Lindsay
Clinical Senior Lecturer, The University of Manchester; Medical Oncology Consultant
The Christie NHS Foundation Trust

Michael Gmachl
Principal Scientist, Regional Center Austria
Boehringer Ingelheim

Roman Hillig
Senior Scientist
Bayer

Sara Mainardi
Senior Postdoctoral Researcher
Netherlands Cancer Institute

Daniel Abankwa
Professor of Cellular Tumour Biology
University of Luxembourg

Angeliki Malliri
Senior Group Leader & Professor of Cell Biology, Cancer Research UK
Manchester Institute
The University of Manchester

Nicolas Bery
Postdoctoral Research Scientist
University of Oxford

Tatu Pantsar
Marie Sklodowska, Curie Fellow
University of Tübingen

YOUR EXPERT SPEAKERS

Darryl McConnell
Senior Vice President & Research Site Head Austria
Boehringer Ingelheim

Steve Kelsey
President, Research & Development
Revolution Medicines

Juan J. Perez
Chief Scientific Officer
Allinky Biopharma

Bert Klebl
Managing Director & Chief Scientific Officer
Lead Discovery Center

Erik D. Wiklund
Chief Business Officer
Targovax

Michael Gmachl
Principal Scientist, Regional Center Austria
Boehringer Ingelheim

Nicolas Bery
Postdoctoral Research Scientist
University of Oxford

Tatu Pantsar
Marie Sklodowska, Curie Fellow
University of Tübingen
In 2019, the first reports of clinical efficacy using direct inhibitors of KRAS G12C were released, already showing great promise for the future implementation of these drugs in the cancer clinic. In parallel, current clinical trial evidence suggests that lung cancers driven by KRAS mutation are also vulnerable to treatment with immune checkpoint inhibitors.

The aim of this workshop is to share our experience of pursuing a RAS translational programme in the clinic across two Cancer Research UK institutes. The first part of the workshop will examine what constitutes a successful biomarker for clinical roll-out, drawing parallels with the progress achieved in other molecular sub-sets of cancer where established treatment approaches are still improving. The second part of the workshop will explore what delegates consider to be the optimal cell line and animal models for study of the MAP kinase pathway and its immunotherapeutic vulnerabilities.

Topics to be covered:
- How are biomarkers successfully translated for the clinical application of small molecules and immuno-therapy?
- What lessons can be taken from other examples of successful small molecule drug targeting in cancer, such as EGFR mutation or ALK re-arrangement?
- How is next generation sequencing being implemented in hospitals?
- What are the optimal tissue culture models for studying RAS-driven cancer?
- What are the optimal animal models for studying RAS-driven cancer?

Dr. Angeliki Malliri completed her bachelors degree in Biology in the University of Patras, Greece and obtained her PhD from the University of Crete, Greece. She worked as a postdoctoral scientist in the Beatson Institute for Cancer Research, Glasgow, UK and the Netherlands Cancer Institute in Amsterdam. She established her independent research group in 2004 in Cancer Research UK Manchester Institute, UK. The focus of her current research is the role of the small GTPase RAC and its regulators in lung tumour formation and progression, including lung tumourigenesis initiated by mutant KRAS. They have also recently instigated a program of research addressing KRAS-mutant isoform selective functions in lung cancer development.

Dr. Colin Lindsay is a Clinical Senior Lecturer in medical oncology, with his time divided 50/50 between research and the clinic. Originally, he trained at the CRUK Beatson Institute and Cancer Centre in Glasgow, where he completed a PhD studying genetically-modified mouse models of RAS- and RAF-driven melanoma. Following that he shifted focus to lung cancer through involvement with the CRUK Stratified Medicine Programme, as well as a two year ESMO translational fellowship at the Gustave Roussy Institute in Villejuif, France. His main interests are 1) the implementation of effective treatment strategies for cancers driven by the MAPK pathway, and 2) successful and efficient translation of genomic results for optimal clinical gain.
## CONFERENCE DAY ONE
### WEDNESDAY 26 FEBRUARY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00</td>
<td>Registration &amp; Networking Coffee</td>
<td></td>
</tr>
<tr>
<td>8.50</td>
<td>Chair’s Opening Remarks</td>
<td></td>
</tr>
</tbody>
</table>
| 9.00  | Combination Approaches to the Use of G12C KRAS Inhibitors               | Julian Downward  
Associate Research Director  
Francis Crick Institute                                                                 |
| 9.30  | Targeting KRAS-Driven Oncogenic Signalling                               | Dwight V. Nissley  
Director, Cancer Research Technology Program; NCI RAS Initiative  
Frederick National Laboratory for Cancer Research |
| 10.00 | Drugging the Other KRAS Mutants                                         | Darryl McConnell  
Senior Vice President & Research Site Head Austria  
Boehringer Ingelheim |
| 10.30 | Speed Networking & Morning Refreshments                                  |                                                                                                |
| 11.30 | Targeting KRAS Singing                                                   | Mariano Barbacid  
AXA.CNIO Professor of Molecular Oncology  
CNIO (Spanish National Cancer Research Center) |
| 12.00 | RAS Protein Flexibility & How to Target Cryptic Pockets to Drug the Undruggable Master Oncogene | Laurent Debussche  
Vice President, Global Head Molecular Oncology Research Therapeutic Area  
Sanofi R&D |
| 12.30 | Strategies to Inhibit RAS-Driven Cancers                                 | Steve Kelsey  
President, Research & Development Revolution Medicines |
| 13.00 | Networking Lunch                                                         |                                                                                                |

### Additional Details
- **RAS-Targeted Drug Discovery Summit Europe**  
February 25-27, 2020 | Vienna, Austria
- **Tel:** +44 203 141 8700  
**Email:** info@hansonwade.com  
**Website:** www.ras-europe.com

---

**9.00 Combination Approaches to the Use of G12C KRAS Inhibitors**

- KRAS G12C inhibitors have proved effective on many G12C KRAS mutant tumour in vitro, in vivo and in clinical trials, but acquired and pre-existing resistance is a problem.
- Several approaches have been taken to establish how best to combine these drugs for more effective treatment of KRAS G12C mutant cancers and minimisation of resistance.
- The response of KRAS G12C mutant lung tumour with these inhibitors profoundly alters the tumour immune microenvironment, allowing ingestion of various effector immune cells: studying the phenotype of these cells suggests optimal combinations between KRAS G12C inhibitors and immunotherapies.

**9.30 Targeting KRAS-Driven Oncogenic Signalling**

- Inhibition of KRAS using small molecule inhibitors.
- KRAS and activation of signaling at the plasma membrane.
- KRAS complexes.

**10.00 Drugging the Other KRAS Mutants**

- Boehringer Ingelheim is taking a systematic approach to discovering drugs for all KRAS mutants.
- The potential approaches to drugging KRAS beyond G12C with small molecules will be discussed.
- Highlights from some of Boehringer Ingelheim’s KRAS programs will be presented.

**11.30 Targeting KRAS Singing**

- Description of a genetically engineered KRAS/TP53-driven mouse lung and pancreatic tumour models driven by the KRAS G12C mutation.
- Targeting the canonical MAPK pathway is unacceptable toxic: Genetic evidence.
- RAF1 as a “non-toxic” key mediator of KRAS oncogenic signalling.

**12.00 RAS Protein Flexibility & How to Target Cryptic Pockets to Drug the Undruggable Master Oncogene**

- RAS is a very flexible protein without any apparent druggable pocket which has resisted three decades of efforts to drug it.
- Cryptic or induced pockets can be identified in addition to so-called S11 pocket.
- DNA-encoded library approach is a powerful approach to drug cryptic pockets such as S11 pocket.

**12.30 Strategies to Inhibit RAS-Driven Cancers**

- SHP2 inhibition.
- Combination strategies.
- Tri-complex small molecule inhibitors of the oncogenic, GTP-bound (ON) form of KRAS.

---
# Accelerating Anti-RAS Drug Discovery Through New Tools & Technologies

### 14.00 Chemotype Evolution: Accelerating Drug Discovery for Challenging Targets
- **Stig Hansen**
  - Chief Executive Officer
  - Carmot Therapeutics

Chemotype Evolution (CE) is a versatile technology that accelerates drug discovery for challenging targets:
- Using this technology, Carmot has discovered novel covalent KRAS G12C inhibitors
- Covalent CE can be leveraged to identify new treatments for KRAS-driven cancers

### 14.30 Revealing New RAS Vulnerabilities with Protein Interference (PROTEINi)
- **Grahame Mckenzie**
  - Chief Scientific Officer
  - PhoreMost

Oncogenic RAS remains largely undrugged:
- PROTEINi identifies new targets which are synthetic lethal with RAS
- PhoreMost’s SITESEEKER platform provides key pharmacophoric information about how to go about drugging these targets

### 15.00 Design of Small Molecule Allosteric Inhibitors of KRAS
- **Juan J. Perez**
  - Chief Scientific Officer
  - Allinky Biopharma

We will present the in vitro and in vivo results of a series of orally available small molecules that were designed following an in silico approach:
- These novel therapeutics bind onto an allosteric site of KRAS

### 15.30 Afternoon Refreshments & Poster Session

---

# Empowering Potent Anti-RAS Drug Discovery with Novel Assays & Strategies

### 16.00 Targeting the Lymph Nodes to Enhance Mutant KRAS-Specific Vaccine Responses
- **Peter DeMuth**
  - Vice President of Research
  - Elicio Therapeutics

Review of Elicio’s lymph node targeting AMP vaccination platform:
- Data showing vaccine-induction of potent mKRAS-specific T cell responses
- Review of Elicio mKRAS clinical development program

### 16.30 Generation & Characterisation of Antibodies Targeting Mutant KRAS Proteins
- **Sreeshaa P. Srinivasa**
  - Senior Vice President
  - Oblique Therapeutics

Generation of selective antibodies:
- Biochemical characterisation
- Functional characterisation in wild type and mutant cancer cell lines

### 17.00 Rush or Crash – “High” Ways or Dead Ends to Tackle RAS
- **Bert Klebl**
  - Managing Director & Chief Scientific Officer
  - Lead Discovery Center

Small molecule RAS modulation:
- RAS shuttling from endomembranes to the plasma membrane
- KRAS stabilisation
- KRAS wild type vs. mutant inhibition

### 17.30 A Subset of Flavaglines Inhibit KRAS Oncogene Activation
- **Krishnaraj Rajalingam**
  - Heisenberg Professor of Cell Biology, Cell Biology Unit
  - University Medical Center Mainz

Novel assays to measure KRAS activation in cells:
- Identification of flavagline derivatives as potent KRAS inhibitors
- Mechanisms and in vivo effects

### 18.00 Chair’s Closing Remarks & End of Day One
### CONFERENCE DAY TWO
**THURSDAY 27 FEBRUARY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30</td>
<td>Coffee &amp; Networking</td>
</tr>
<tr>
<td>8.55</td>
<td>Chair’s Opening Remarks</td>
</tr>
<tr>
<td></td>
<td><strong>Targeting the Previously Undruggable: Translational &amp; Clinical Perspective of Targeting RAS</strong></td>
</tr>
<tr>
<td>9.00</td>
<td><strong>Rigosertib is a Unique Small Molecule RAS Antagonist: Scientific &amp; Clinical Studies</strong></td>
</tr>
<tr>
<td></td>
<td>Steven M. Fruchtman, President &amp; Chief Executive Officer, Onconova Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Rigosertib targets RAS as a RAS mimetic interacting with its effector proteins</td>
</tr>
<tr>
<td></td>
<td>Role of genetic and RAS pathway mutations in MDS</td>
</tr>
<tr>
<td></td>
<td>An update of RAS in the clinic</td>
</tr>
<tr>
<td>9.30</td>
<td><strong>Vaccinating Against Mutant RAS – Results from TG01 Phase I/II Trial</strong></td>
</tr>
<tr>
<td></td>
<td>Erik D. Wiklund, Chief Business Officer, Targovax</td>
</tr>
<tr>
<td></td>
<td>Results from 32-patient TG01 trial in resected pancreatic cancer</td>
</tr>
<tr>
<td></td>
<td>Robust immune responses demonstrated against KRAS</td>
</tr>
<tr>
<td></td>
<td>Overview of clinical and molecular outcomes</td>
</tr>
<tr>
<td>10.00</td>
<td><strong>RAS Mutation: Being Precise in Precision Medicine</strong></td>
</tr>
<tr>
<td></td>
<td>Colin Lindsay, Clinical Senior Lecturer, The University of Manchester; Medical Oncology Consultant, The Christie NHS Foundation Trust</td>
</tr>
<tr>
<td></td>
<td>Clinical and translational perspective on previous clinical trial disappointments with RAS targeting</td>
</tr>
<tr>
<td></td>
<td>Looking towards immunotherapy combinations with small molecules in the lung cancer landscape</td>
</tr>
<tr>
<td></td>
<td>Examination of whole genome/exome sequencing results from RAS mutant lung cancer</td>
</tr>
<tr>
<td>10.30</td>
<td>Morning Refreshments &amp; Networking</td>
</tr>
<tr>
<td></td>
<td><strong>Enabling Structure Guided &amp; Selective Targeting of RAS Proteins</strong></td>
</tr>
<tr>
<td>11.00</td>
<td><strong>Disruption of the RAS-SOS1 Interaction – Enabling Lead Discovery by a Combination of High-Throughput &amp; Fragment Screening</strong></td>
</tr>
<tr>
<td></td>
<td>Roman Hillig, Senior Scientist, Bayer</td>
</tr>
<tr>
<td></td>
<td>Combination of high-throughput &amp; fragment screening enabled a new approach to target KRAS</td>
</tr>
<tr>
<td></td>
<td>Structure-guided optimisation of potent and selective SOS1 inhibitors</td>
</tr>
<tr>
<td></td>
<td>Cellular data support a possible combination potential of SOS1 inhibitors with covalent inhibitors of KRAS&lt;sup&gt;g12c&lt;/sup&gt;</td>
</tr>
<tr>
<td>11.30</td>
<td><strong>Discovery of BI-3406: A Potent &amp; Selective SOS1: KRAS Inhibitor Opens a New Approach for Treating KRAS-Driven Tumours</strong></td>
</tr>
<tr>
<td></td>
<td>Michael Gmachl, Principal Scientist, Regional Center Austria, Boehringer Ingelheim</td>
</tr>
<tr>
<td></td>
<td>BI 3406 selectively binds to SOS1 and blocks the interaction with KRAS, irrespective of the KRAS mutation</td>
</tr>
<tr>
<td></td>
<td>BI 3406 causes RAS GTP and pERK reduction and inhibits cell growth of KRAS mutated cell lines, carrying most of the typical KRAS mutations (i.e. G12D, G12V, G13D and others)</td>
</tr>
<tr>
<td></td>
<td>BI 3406, when administered orally to tumour bearing mice, causes a dose dependent tumour static effect that can be converted into regressions when combined with MEK1 inhibition</td>
</tr>
<tr>
<td>12.00</td>
<td><strong>Drug Development Against KRAS Surrogate Targets</strong></td>
</tr>
<tr>
<td></td>
<td>Daniel Abankwa, Professor of Cellular Tumour Biology, University of Luxembourg</td>
</tr>
<tr>
<td></td>
<td>Selective targeting of KRAS, but not H-RAS may specifically eliminate cancer stem cells (CSC)</td>
</tr>
<tr>
<td></td>
<td>To this end, we developed novel inhibitors against PDE6D/ PDEdelta, a surrogate target of KRAS, which realise KRAS selectivity and thus anti-CSC activity</td>
</tr>
<tr>
<td></td>
<td>Secondly, we describe a new mechanism of how Hsp90 inhibition likewise selectively targets KRAS; novel small-molecule Hsp90/Cdc37 protein-protein interface inhibitors are presented</td>
</tr>
</tbody>
</table>
The recent RAS-Targeted Drug Discovery meeting in Boston was an exciting and educational opportunity bringing together basic and clinical scientists studying the RAS pathway and the clinical implications of the dysregulation of this pathway. Scientists presented their concepts on how they believe the pathway; until recently difficult to influence; can now be modulated. And how this progress has translated into clinical trials in various diseases driven by mutations of that pathway.

Steven M. Fruchtman, President & Chief Executive Officer, Onconova Therapeutics
WHY ARE OUR EXPERT SPEAKERS GETTING INVOLVED AT THE SUMMIT?

“"The field of RAS inhibitory drugs has exploded in the last few years and this meeting will be an excellent opportunity to catch up on the latest developments in this fast moving area’’

Julian Downward
Associate Research Director
Francis Crick Institute

“The long-awaited breakthroughs in targeting mutant RAS are now with us, and research and development in the RAS field is advancing rapidly. This meeting will bring together top researchers in the field. Attendance and participation will be critical to stay with the field’’

Steve Kelsey
President, Research & Development
Revolution Medicines

“I am hoping that this event will bring together opinion leaders from both academia and drug discovery in order to deliver a truly translational meeting focused on how best to tackle oncogenic RAS’’

Grahame Mckenzie
Chief Scientific Officer
PhoreMost

“Targeting oncogenic KRAS signalling is one of the most exciting challenges in cancer biology. Recent clinical trials with KRAS G12C specific inhibitors open up a first glimpse on the potential of targeting oncogenic KRAS in general. Networking, exchange of ideas and experiences in the KRAS field is one of the major values of this meeting’’

Michael Gmachl
Principal Scientist, Regional Center Austria
Boehringer Ingelheim

“This meeting provides a great opportunity to discuss new approaches to this rapidly advancing area in cancer therapeutics’’

Stig Hansen
Chief Executive Officer
Carmot Therapeutics

Stig Hansen
Chief Executive Officer
Carmot Therapeutics

Tel: +44 203 141 8700   Email: info@hansonwade.com
www.ras-europe.com
BECOME A COMMERCIAL PARTNER

60+ ATTENDEES
7+ HOURS OF DEDICATED NETWORKING
1 INTERACTIVE WORKSHOP
23+ REAL WORLD CASE STUDIES

Benefit from Market Intelligence
Drugging the previously undruggable RAS targets creates tremendous opportunity to address the current unmet clinical need. Hear how and where pharmaceutical giants are looking for services and solutions to facilitate their R&D platforms and match your solutions accordingly.

Raise Brand Awareness
Benefit from pre and post conference exposure to our drug discovery KOL community and increase market share through unique branding formats. Also, differentiate your discovery, pre-clinical and translational services from other solution providers.

Position Yourself as an Industry Expert
With the emergence of biotech companies focused on developing mutant-targeted RAS therapies, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent expertise in front of the key decision-makers in the field.

Meet & Network with Industry Pioneers
With a room full of drug developers looking to see how they can effectively translate their exciting early discovery efforts into safe and effective therapeutics, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions.

Generate Commercial Collaborations
Make sure your hottest prospects are in the room and part of the discussion, by having a wishlist of your choice contacted in advance of the event.

SENIORITY

Director & C-Level: 45%
Scientists & Team Leaders: 25%
Other: 20%

COMPANY BY TYPE

Large Pharma & Biotech: 72%
Academic Institutions: 17%
Technology Companies: 11%

*Based on audience breakdown from RAS- Targeted Drug Discovery Boston 2019

BECOME A PARTNER

Bashir Langhi
Partnerships Director
E: sponsor@hansonwade.com
T: +44 (0)203 141 8797

Tel: +44 203 141 8700  Email: info@hansonwade.com

www.ras-europe.com
RAS- Targeted Drug Discovery Summit Europe
February 25-27, 2020  |  Vienna, Austria

READY TO REGISTER?
3 EASY WAYS TO BOOK

www.ras-europe.com
Tel: +44 203 141 8700
Email: register@hansonwade.com

SECURE YOUR PLACE

Industry Pricing*

<table>
<thead>
<tr>
<th></th>
<th>Register &amp; Pay By Friday 25 October (Save Up To €900)</th>
<th>Standard Pricing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
<td>€2,198</td>
<td>€3,098</td>
</tr>
<tr>
<td>Conference Only</td>
<td>€1,899</td>
<td>€2,699</td>
</tr>
<tr>
<td>Workshop Only</td>
<td>€399</td>
<td>€499</td>
</tr>
</tbody>
</table>

Academic Pricing

<table>
<thead>
<tr>
<th></th>
<th>Register &amp; Pay By Friday 25 October (Save Up To €900)</th>
<th>Standard Pricing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
<td>€1,698</td>
<td>€2,598</td>
</tr>
<tr>
<td>Conference Only</td>
<td>€1,499</td>
<td>€2,299</td>
</tr>
<tr>
<td>Workshop Only</td>
<td>€299</td>
<td>€399</td>
</tr>
</tbody>
</table>

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5+ delegates

Please note that discounts are only valid when three or more delegates from the same company book and pay at the same time. Discounts cannot be used in conjunction with any other offer and are only eligible on industry pricing. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy:

Cancellations must be received in writing if the cancellation is received more than 14 days before the conference. A full refund of the full fee will be issued. Substitution from the same organization can be made at any time.

Hilton Vienna Plaza
Schottenring 11, 1010 Wien, Austria
For further information or assistance, please visit https://www3.hilton.com/en/hotels/austria/hilton-vienna-plaza-VIEPWTW/index.html?WT.mc_id=zELWAKNOEMEAI12DMH3LocalSearch4DGGenericx6VIEPWTW

SAVE valuable time and resources by learning how the leading companies in the space are advancing their anti-RAS strategies

GAIN first-hand insights on challenges and strategies on how to robustly translate promising direct anti-RAS therapies into clinical development and increase your success rate

FORM lasting connections by engaging directly with colleagues from the leading pharma and biotech companies actively developing anti-RAS therapies and seeking the best solutions, in an intimate environment

DATA PROTECTION: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Data Protection Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Tel: +44 203 141 8700
Email: info@hansonwade.com

www.ras-europe.com